STOCK TITAN
  1. Home
  2. News
  3. IGXT

IntelGenx Technologies Corp - IGXT STOCK NEWS

Welcome to our dedicated news page for IntelGenx Technologies (Ticker: IGXT), a resource for investors and traders seeking the latest updates and insights on IntelGenx Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IntelGenx Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IntelGenx Technologies's position in the market.

News
IntelGenx Announces Changes to its Board of Directors
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) announces the resignation of Frank Stegert and Srinivas Rao from the Board of Directors and the appointment of Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
management
-
News
IntelGenx Announces Shareholder Approval of Financing Transactions
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) shareholders approve financing transactions with atai Life Sciences AG, including the issuance of common stock and an increase in authorized shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.33%
Tags
none
-
News
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Rhea-AI Summary
IntelGenx Corp. (IGX) Announces Phase 2 MONTPARK Trial for Montelukast VersaFilm to Treat Parkinson’s Disease. The trial is approved by Swedish Medical Products Agency and aims to investigate the efficacy of oral high-dose Montelukast on the progression of early-to-moderate PD. Expected to begin recruiting patients in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting
Rhea-AI Summary
IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) Urges Shareholders to Vote on Key Proposals at Upcoming Special Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IntelGenx Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
IntelGenx Technologies Corp. (IGX) reported a revenue of $318,000 for Q3-2023, with a net comprehensive loss of $2.5 million. Recent developments include receiving a purchase order for RIZAFILM® from Gensco Pharma, and completing patient enrollment for a clinical trial of Montelukast VersaFilm® in Alzheimer’s patients. The company also announced several other positive developments, including a research collaboration with Karolinska University Hospital for the treatment of Parkinson’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray
Rhea-AI Summary
IntelGenx Corp. has announced a further amendment to their agreement with Tilray Brands Inc. for the co-development and commercialization of cannabinoid-infused VersaFilm® products. The amendment includes an initial purchase order for three SKUs totaling 130,000 filmstrips and allows for the co-development and commercialization of CBD, THC, and combination THC:CBD products with additional partners. The agreement also removes any royalties paid to or from Tilray.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
IntelGenx to Report Third Quarter 2023 Financial Results on November 9, 2023 – Conference Call to Follow
Rhea-AI Summary
IntelGenx Technologies Corp. will release its third quarter 2023 financial results on November 9, 2023, after market close. The accompanying conference call will be hosted by the CEO, President, and Chairman to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
conferences earnings
-
News
IntelGenx Provides RIZAFILM® U.S. Commercialization Update
Rhea-AI Summary
IntelGenx receives first purchase order for RIZAFILM® from Gensco Pharma, triggering upfront deposit and milestone payments. Expects to ship product in Q1-2024 for immediate launch. CEO expresses confidence in partnership and positive impact on balance sheet.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
IntelGenx Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film
Rhea-AI Summary
IntelGenx Corp. provides regulatory update on Buprenorphine Buccal Film. FDA grants priority review with goal date for review of the Amendment on March 8, 2024, unless inspection required. CEO optimistic about FDA decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)
Rhea-AI Summary
IntelGenx Technologies Corp. announces closing of non-brokered private placement with atai Life Sciences AG for gross proceeds of approximately US$3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock IGXT logo
IntelGenx Technologies Corp

OTC:IGXT

IGXT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IGXT Stock Data

32.33M
135.32M
22.4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
Saint Laurent

About IGXT

intelgenx is a montreal based company devoted to developing its novel and innovative proprietary technologies for enhanced drug delivery. our business strategy is to apply our proprietary drug delivery technologies to improve existing drug compounds with proven efficacy and safety and, in conjunction with strategic development and distribution partners, reintroduce these drug compounds to the market as branded products with improved deliverability and efficacy. intelgenx is capable, through itself and strategic partners, of offering its partners full service pharmaceutical development from formulation development, clinical development and regulatory activities to manufacturing and packaging. intelgenx’s highly qualified team has the capability to work with new chemical entities (nces) or established therapeutic active pharmaceutical ingredients (apis) where the use of innovative new drug delivery systems offer significant competitive advantage or the opportunity for product exten